Enfusion, Inc. (NYSE:ENFN) Stake Boosted by New York State Common Retirement Fund

New York State Common Retirement Fund boosted its stake in shares of Enfusion, Inc. (NYSE:ENFN) by 23.8% during the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 1,926,968 shares of the company’s stock after buying an additional 370,498 shares during the period. New York State Common Retirement Fund owned about 1.50% of Enfusion worth $19,848,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors also recently made changes to their positions in the company. Rhumbline Advisers lifted its holdings in shares of Enfusion by 3.0% in the fourth quarter. Rhumbline Advisers now owns 62,464 shares of the company’s stock valued at $643,000 after purchasing an additional 1,796 shares in the last quarter. JPMorgan Chase & Co. raised its position in Enfusion by 612.4% during the third quarter. JPMorgan Chase & Co. now owns 208,022 shares of the company’s stock valued at $1,974,000 after buying an additional 178,821 shares during the period. Barclays PLC lifted its stake in Enfusion by 251.4% in the 3rd quarter. Barclays PLC now owns 86,039 shares of the company’s stock worth $817,000 after acquiring an additional 61,554 shares in the last quarter. Geode Capital Management LLC boosted its position in Enfusion by 7.3% during the 3rd quarter. Geode Capital Management LLC now owns 1,029,366 shares of the company’s stock worth $9,770,000 after acquiring an additional 70,367 shares during the period. Finally, Wellington Management Group LLP boosted its position in Enfusion by 6.7% during the 3rd quarter. Wellington Management Group LLP now owns 976,296 shares of the company’s stock worth $9,265,000 after acquiring an additional 61,032 shares during the period. 81.05% of the stock is currently owned by institutional investors and hedge funds.

Insider Activity

In related news, CEO Oleg Movchan sold 2,771 shares of the firm’s stock in a transaction that occurred on Tuesday, January 7th. The stock was sold at an average price of $10.13, for a total value of $28,070.23. Following the transaction, the chief executive officer now directly owns 526,702 shares of the company’s stock, valued at approximately $5,335,491.26. This trade represents a 0.52 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. Also, CFO Bradley Herring sold 24,443 shares of the business’s stock in a transaction that occurred on Friday, December 20th. The stock was sold at an average price of $10.61, for a total value of $259,340.23. Following the completion of the sale, the chief financial officer now owns 270,503 shares of the company’s stock, valued at approximately $2,870,036.83. This trade represents a 8.29 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 57,367 shares of company stock worth $591,335. 36.44% of the stock is owned by corporate insiders.

Enfusion Stock Performance

Shares of ENFN opened at $11.50 on Friday. The firm has a market cap of $1.48 billion, a PE ratio of 287.45, a PEG ratio of 1.85 and a beta of 0.96. The firm’s 50 day moving average price is $10.82 and its 200 day moving average price is $9.66. Enfusion, Inc. has a twelve month low of $7.83 and a twelve month high of $11.80.

Analyst Upgrades and Downgrades

A number of analysts have recently issued reports on ENFN shares. Piper Sandler increased their price target on shares of Enfusion from $10.00 to $11.50 and gave the stock a “neutral” rating in a research report on Monday, December 23rd. Stifel Nicolaus increased their target price on shares of Enfusion from $11.00 to $13.00 and gave the stock a “buy” rating in a research report on Wednesday, December 18th. Finally, William Blair restated a “market perform” rating on shares of Enfusion in a report on Monday, January 13th. Two research analysts have rated the stock with a sell rating, two have given a hold rating and two have assigned a buy rating to the company’s stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Hold” and a consensus price target of $10.50.

About Enfusion

Enfusion, Inc provides software-as-a-service solutions for investment management industry in the United States, Europe, the Middle East, Africa, and the Asia Pacific. The company provides Portfolio Management System, which generates a real-time investment book of record that consists of valuation and risk tools, which allows users to analyze aggregated or decomposed portfolio data for chief investment officers (CIOs) and portfolio managers; and Order and Execution Management System that enables portfolio managers, traders, compliance teams, and analysts to electronically communicate trade orders for a variety of asset classes, manage trade orders, and systemically enforce trading regulations and internal guidelines.